Sevan Names New Chief Financial Officer
28.4.2020 16:00:00 EEST | Business Wire | Press release
Sevan Multi-Site Solutions, Inc. (Sevan), a global leader in innovative design, program management, construction services and data analytics, today announced Paul Evans has been named the company’s Chief Financial Officer (CFO). Evans will oversee Sevan’s global finance functions including accounting, financial planning and analysis, risk management and mergers & acquisitions. He will also play an integral role in shaping the strategic direction of the company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200428005335/en/
Paul Evans (Photo: Business Wire)
Evans brings more than 20 years of leadership experience to the role. Before joining Sevan, he served as Interim Chief Executive Officer and Board Member at Hill International, Chief Financial Officer at MYR Group, Chief Executive Officer at Conex Energy Corporation and Treasurer at NorthWestern Energy. His background and financial expertise include significant experience with operational management and accounting, debt and equity financing, investor relations, tax, budgeting, forecasting, audits, capital allocation, network optimization, contingency planning and information technology.
“Paul brings extraordinary experience in corporate and operational finance across a variety of industries and has been responsible for leading global teams supporting large-scale engineering and construction operations,” said Jim Evans, President and CEO of Sevan. “I am excited to have Paul join our executive office and team at such an important time for our business. I am confident Sevan will benefit from his experiences and perspective as we accelerate our path to grow.”
In December 2019, ABS Capital Partners invested $17.5 million in Sevan to support continued growth and scalability. ABS Capital Partners is a leading late-stage growth company investor.
“Sevan has grown organically for the past nine years since the company’s inception, and ABS Capital is Sevan’s first outside investor,” said Paul Evans. “I look forward to helping Sevan continue to grow in a sustainable way while providing strategic expertise through all financial operations, acquisitions, integration and beyond.”
Paul Evans earned a Master of International Management from Thunderbird School of Global Management in Phoenix, Arizona and a Bachelor of Business Administration – Accounting from Stephen F. Austin State University in Nacogdoches, Texas. He is also a Certified Public Accountant. Evans is a U.S. Army veteran, and a dual citizen of the United States and United Kingdom.
Sevan is a 450-person project management firm headquartered in Downers Grove, Illinois with an international office in London. Paul will be based out of Sevan’s headquarters.
Sevan has been recognized as an Employee-Rated Great Place to Work for six consecutive years. In 2018 Great Place to Work® and FORTUNE ranked Sevan #29 on the list of the 100 Best Medium Workplaces. A full list of awards and rankings Sevan earned to date is available on Sevan’s Website.
About Sevan
The vision of Sevan Multi-Site Solutions (Sevan) is to be the best in the world at delivering innovative design, program management, construction services and data analytics to organizations with multiple sites. Sevan has a passion for sustaining people, the environment and its clients’ businesses. Sevan helps iconic global brands—including 7-Eleven, AAFES, Albertsons, BP, Bento Box, Carrols Corporation, Chipotle, DaVita, HCA Healthcare, Hallmark, Kroger, McDonald’s, Marathon, Office Depot, Starbucks, Sunoco, Walgreens Boots Alliance and Walmart. Sevan rolls out Multi-Site initiatives efficiently, predictably and transparently. Applying breakthrough technology solutions, Sevan optimizes new builds, rebuilds, remodels and renovations. The company’s expertise spans numerous market sectors including banking, fuel and convenience store, government, restaurant, grocery, retail, healthcare, housing and hospitality industries. For more information, visit www.sevansolutions.com.
For more information please contact Hafsa Mahmood by calling 312.285.0590 or via e-mail at hafsa.mahmood@sevansolutions.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200428005335/en/
Contact information
Hafsa Mahmood
Manager, Marketing & Communications April 28, 2020
Phone: 312.285.0590
Email:
hafsa.mahmood@sevansolutions.com
Website:
www.sevansolutions.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 09:10:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across systems, identify root causes, and execute actions within governed guardrails. iRun combines AI agents and human expertise to shift opera
Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom